ClinicalTrials.gg
Active, not recruitingNCT03816163Updated Oct 14, 2026

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

A Phase 2 interventional study of zolbetuximab and nab-paclitaxel in Pancreatic Cancer, Metastatic Pancreatic Cancer and Metastatic Pancreatic Adenocarcinoma, sponsored by Astellas Pharma Global Development, Inc.. Active, not recruiting at 136 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

Updated Oct 14, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
393
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,851 studies in Pancreatic Neoplasms with a site in United States — 300 open to participants now, 474 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
92nd of 1,574
393 · median 37
Started
2019
with 93 others
Phase 2
488 of 1,851
45 open now
Primary completion
2026-10
later than 105 of 473 live
Registered
1,213th of 1,851
by date

Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, this one is the 92nd largest by enrollment of the 1,574 interventional ones that give a count, is one of 94 that started in 2019, is one of 488 in phase 2, reaches primary completion later than 105 of the 473 other live ones, and was the 1,213th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

300 of the 1,851 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

295 more — sign in →

All 300 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,851 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2 (CLDN18.2) in their tumor. Zolbetuximab is thought to work by attaching to CLDN 18.2 in their tumor. This switches on the body's immune system to attack the tumor. Zolbetuximab is a potential treatment for people with pancreatic cancer.

There is an unmet medical need to treat people with pancreatic cancer. This study will help find the dose of zolbetuximab to be used with chemotherapy and provide more information on this treatment in adults with metastatic pancreatic cancer. The study is currently ongoing globally. People in this study will be treated with either zolbetuximab and chemotherapy or chemotherapy by itself.

The study's main aims are to find a suitable dose of zolbetuximab to be used with chemotherapy in the second part of this study, to check if zolbetuximab and chemotherapy compared to chemotherapy by itself can improve the survival of people with pancreatic cancer, and to check the safety of zolbetuximab when given with chemotherapy and how well people cope with medical problems during the study.

Adults with metastatic pancreatic cancer can take part. Their cancer is metastatic, has the CLDN18.2 marker in a tumor sample and has not previously been treated with chemotherapy. Metastatic means the cancer has spread to other parts of the body. People cannot take part are if they have recently had radiotherapy and have not recovered, need to take medicines to suppress their immune system, have history of nervous system metastases from their pancreatic cancer, or they have other active cancers that need treatment. People who have a specific heart condition or infections also cannot take part.

This study will be in 2 parts. Part 1 is called the Safety Lead-in Phase. Groups of people will receive 1 of 2 different doses of zolbetuximab: a lower dose or a higher dose, both together with chemotherapy. A medical expert panel will check the results and decide the dose to use in Part 2.

Part 2 is called the Randomization Phase. People will be put in 1 of 2 groups by chance and will be given different treatments either zolbetuximab and chemotherapy or chemotherapy by itself. The chance of receiving zolbetuximab and chemotherapy is twice as high as receiving chemotherapy by itself. In both parts of the study, zolbetuximab and chemotherapy or chemotherapy by itself will be given through a vein. This is called an infusion. Each treatment cycle is 4 weeks (28 days) long and people will have either 2 infusions of zolbetuximab and 3 infusions of chemotherapy or 3 infusions of chemotherapy by itself during each treatment cycle. People will visit the clinic on certain days during their treatment. The study doctors will check for any medical problems from zolbetuximab. Also, people in the study will have a health check including blood tests. On some visits they will also have scans to check for any changes in their cancer. Tumor samples will be taken before treatment if a previous sample is not available. People will have the option of giving a tumor sample after treatment has finished. People will visit the clinic after they stop treatment. They will be asked about any medical problems and will have a health check including blood tests. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their treatment or not.

Astellas is terminating the zolbetuximab pancreatic development program from Dec 2025 (following the final OS analysis in Oct 2025). Active subjects may remain on treatment if the investigator determines they are receiving benefit from it. The Survival follow-up period is no longer required.

Read the detailed description

This study will have a safety lead in phase and a randomization phase.

03

Conditions studied

  • Pancreatic Cancer
  • Metastatic Pancreatic Cancer
  • Metastatic Pancreatic Adenocarcinoma

Keywords

  • metastatic pancreatic cancer
  • IMAB362
  • nab-paclitaxel
  • gemcitabine
  • zolbetuximab
  • metastatic pancreatic adenocarcinoma
  • pancreatic cancer
  • CLDN 18.2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A female subject is eligible to participate if she is not pregnant or lactating and at least 1 of the following conditions applies:

    • Not a woman of (WOCBP) OR
    • WOCBP who agrees to follow the guidance throughout the treatment period and for at least 6 months after the final study drug administration.
  • Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study drug administration.
  • Female subject must not donate ova starting at screening and throughout the study period, and for 6 months after the final study drug administration.
  • A male subject with female partner(s) of child-bearing potential must agree to use contraception during the treatment period and for at least 6 months after the final study drug administration.
  • A male subject must not donate sperm during the treatment period and for at least 6 months after the final study drug administration.
  • Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study drug administration.
  • Subject agrees not to participate in other interventional studies while receiving study drug in present study.
  • Subject has or cytologically confirmed adenocarcinoma of pancreas.
  • Subjects must have pancreatic adenocarcinoma that has not been previously treated with chemotherapy.

    • Prior treatment with fluorouracil (5-FU) or GEM administered as a radiation sensitizer during and up to 4 weeks after radiation therapy is allowed
    • If a subject received therapy, tumor recurrence or disease progression must have occurred at least 6 months after completing the last dose of the adjuvant therapy.
    • Subjects whose disease progressed on prior treatment with Nab-P and GEM are not eligible.
  • Subject has a (s) on at least 1 metastatic site based on 1.1 within 28 days prior to randomization. For subjects with only 1 measurable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy.
  • Subject's tumor sample has CLDN18.2 expression in ≥ 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central immunohistochemistry (IHC) testing
  • Subject has (ECOG) performance status of 0 or 1.
  • Subject has predicted ≥ 12 weeks.
  • Subject must meet all of the following criteria based on the laboratory tests that will be collected within 14 days prior to randomization. In case of multiple laboratory data within this period, the most recent data should be used.

    • ≥ 9 g/dl (no transfusion within 14 days of start of study treatment)
    • ≥ 1.5 x 10\^9/L
    • ≥ 100 x 10\^9/L
    • Albumin ≥ 2.5 g/dL
    • Total ≤ 1.5 x (ULN)
    • (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN without liver metastases (≤ 5 x ULN if liver metastases are present)
    • Estimated ≥ 30 mL/min
    • /international normalized ratio (INR) and partial thromboplastin time ≤ 1.5 x ULN (except for subjects receiving anticoagulation therapy)

Exclusion criteria

Exclusion Criteria:

  • Subject has received other treatment within 28 days prior to randomization.
  • Subject has received radiotherapy for pancreatic adenocarcinoma ≤ 14 days prior to randomization and has not recovered from any related toxicity.
  • Subject has received systemic therapy, including systemic within 14 days prior to randomization. Subject using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone), receiving a single dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use are allowed.
  • Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibody, including humanized or chimeric antibodies.
  • Subject has known immediate or delayed , intolerance or to any component of study treatment.
  • Subject has a known history of a positive test for infection or known active (positive HBs antigen [Ag]) or infection. NOTE: Screening for these infections should be conducted per local requirements.

    1. For subjects who are negative for HBs Ag, but hepatitis B core antibody positive, a hepatitis B virus DNA test will be performed and if positive, the subject will be excluded.
    2. Subjects with positive hepatitis C serology but negative hepatitis C virus RNA test results are eligible.
    3. Subjects treated for hepatitis C with undetectable viral load results are eligible.
  • Subject has a history of interstitial pneumonia or pulmonary fibrosis.
  • Subject has pleural effusion or ascites ≥ Grade 3.
  • Subject has an active disease that has required systemic treatment in the past 3 months prior to randomization.
  • Subject has active infection requiring systemic therapy that has not completely resolved per investigator judgment within 7 days prior to randomization.
  • Subject has significant cardiovascular disease, including:

    • Congestive heart failure (defined as Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis within 6 months prior to randomization;
    • History of ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes);
    • > 450 msec for male subjects; QTc interval > 470 msec for female subjects;
    • Cardiac arrhythmias requiring anti-arrhythmic medications (Subjects with rate controlled atrial fibrillation for > 1 month prior to randomization.)
  • Subject has a history of central nervous system metastases and/or carcinomatous meningitis from pancreatic adenocarcinoma.
  • Subject has known peripheral sensory neuropathy ≥ Grade 2 unless the absence of deep tendon reflexes is the sole neurological abnormality.
  • Subject has had a major surgical procedure ≤ 28 days prior to randomization.
  • Subject without complete recovery from a major surgical procedure ≤ 14 days prior to randomization.
  • Psychiatric illness or social situations that would preclude study compliance.
  • Subject has another for which treatment is required.
  • Subject has any concurrent disease, infection or co-morbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
393 participants (actual)

Study arms

  • Experimental
    zolbetuximab +nab-paclitaxel + gemcitabine

    Participants will be treated with zolbetuximab in combination with nab-paclitaxel and gemcitabine for the phase 1 portion of the study to establish the recommended dose of zolbetuximab for the phase 2 portion. In the phase 2 portion, the participants will be treated with zolbetuximab at dose determined by the phase 1 portion of the study in combination with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.

    Drug: zolbetuximab · Drug: nab-paclitaxel · Drug: gemcitabine

  • Active comparator
    nab-paclitaxel + gemcitabine

    Participants will be treated with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.

    Drug: nab-paclitaxel · Drug: gemcitabine

Interventions

  • Administered as an intravenous infusion.

    Also known as: IMAB362

  • Administered as an intravenous infusion

  • Administered as an intravenous infusion

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLT) - (safety lead in)

    Incidence of dose limiting toxicities.

    Time frame: Up to 28 days

  2. Overall Survival (OS)

    OS is defined as the time from the date of randomization until the date of death from any cause.

    Time frame: Up to 79 months

  3. Safety assessed by Adverse Events (AEs)

    An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.

    Time frame: From signing inform consent form until 90 days after the last dose of the study drug (Up to 82 months)

  4. Safety assessed by incidence of serious adverse events (SAE)

    Adverse Event (AE) is considered "serious" if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect, hospitalization, or medically important event.

    Time frame: From signing inform consent form until 90 days after the last dose of the study drug (Up to 82 months)

  5. Safety assessed by incidence of treatment emergent adverse events (TEAE)

    Treatment Emergent Adverse Event (TEAE) is defined as any AE which starts, or worsens, after the first dose of study drug through 30 days after the last dose of study drug.

    Time frame: From first dose up to 30 days after last dose (Up to 80 months)

  6. Number of participants with laboratory value abnormalities and/or adverse events (AEs)

    Number of participants with potentially clinically significant laboratory values.

    Time frame: From first dose up to 30 days after last dose (Up to 80 months)

  7. Number of participants with vital sign abnormalities and /or adverse events (AEs)

    Number of participants with potentially clinically significant vital sign values.

    Time frame: From first dose up to 30 days after last dose (Up to 80 months)

  8. Number of participants with electrocardiograms (ECG) abnormalities and or adverse events

    12-lead ECGs will be recorded. Prior to the ECG, participants should rest in supine position for 10 minutes. ECGs will be read and assessed locally.

    Time frame: From first dose up to 30 days after last dose (Up to 80 months)

  9. Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse events

    Number of participants with potentially clinically significant ECOG performance status values. ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.

    Time frame: From first dose up to 30 days after last dose (Up to 80 months)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from the date of randomization until the date of radiological progressive disease (PD) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 by investigator evaluation or death from any cause, whichever is earliest.

    Time frame: Up to 79 months

  2. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants who have a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by investigator evaluation per RECIST 1.1.

    Time frame: Up to 79 months

  3. Number of anti-drug antibody (ADA) Positive Participants

    Immunogenicity will be measured by the number of participants that are ADA positive.

    Time frame: Up to 79 months

  4. Disease Control Rate (DCR)

    DCR is defined as the proportion of participants who have best overall response of stable disease, complete response (CR) or partial response (PR) as assessed by investigator evaluation per RECIST 1.1

    Time frame: Up to 79 months

  5. Duration Of Response (DOR)

    DOR is defined as the time from the date of the first response (CR/PR) until the date of progressive disease as assessed by investigator evaluation per RECIST 1.1 or date of death from any cause, whichever is earliest.

    Time frame: Up to 79 months

  6. Change in CA (Cancer Antigen) 19-9

    Change from baseline in serum CA19-9 will be assessed.

    Time frame: Up to 79 months

  7. PK of zolbetuximab: Concentration Immediately Prior to Dosing (Ctrough)

    Ctrough will be derived from the PK serum samples collected.

    Time frame: Up to 79 months

  8. PK of Nab-P: Area Under the Concentration-time Curve from the Time of Dosing Extrapolated to Time Infinity (AUCinf)

    AUCinf will be derived from the PK plasma samples collected.

    Time frame: Up to 30 days

  9. PK of Nab-P: Area Under the Concentration-time Curve from the Time of Dosing Until the Last Measurable Concentration (AUClast)

    AUClast will be derived from the PK plasma samples collected.

    Time frame: Up to 30 days

  10. PK of Nab-P: Maximum Concentration (Cmax)

    Cmax will be derived from the PK plasma samples collected.

    Time frame: Up to 30 days

  11. PK of Nab-P: Time of Maximum Concentration (Tmax)

    Tmax will be derived from the PK plasma samples collected.

    Time frame: Up to 30 days

  12. PK of Nab-P: Terminal Elimination Half-life (T1/2)

    T1/2 will be derived from the PK plasma samples collected.

    Time frame: Up to 30 days

  13. PK of Nab-P: Clearance (CL)

    CL will be derived from the PK plasma samples collected.

    Time frame: Up to 30 days

  14. PK of Nab-P: Volume of Distribution During the Terminal Phase (Vz)

    Vz will be derived from the PK plasma samples collected.

    Time frame: Up to 30 days

  15. PK of gemcitabine: Area Under the Concentration-time Curve from the Time of Dosing Extrapolated to Time Infinity (AUCinf)

    AUCinf will be derived from the PK plasma samples collected.

    Time frame: Up to 30 days

  16. PK of gemcitabine: Area Under the Concentration-time Curve from the Time of Dosing Until the Last Measurable Concentration (AUClast)

    AUClast will be derived from the PK plasma samples collected.

    Time frame: Up to 30 days

  17. PK of gemcitabine: Maximum Concentration (Cmax)

    Cmax will be derived from the PK plasma samples collected.

    Time frame: Up to 30 days

  18. PK of gemcitabine: Time of Maximum Concentration (Tmax)

    Tmax will be derived from the PK plasma samples collected.

    Time frame: Up to 30 days

  19. PK of gemcitabine: Terminal Elimination Half-life (T1/2)

    T1/2 will be derived from the PK plasma samples collected.

    Time frame: Up to 30 days

  20. PK of gemcitabine: Clearance (CL)

    CL will be derived from the PK plasma samples collected.

    Time frame: Up to 30 days

  21. PK of gemcitabine: Volume of Distribution During the Terminal Phase (Vz)

    Vz will be derived from the PK plasma samples collected.

    Time frame: Up to 30 days

  22. Health Related Quality of Life (HRQoL) measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC-QLQ-C30)

    The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." For functional scales, higher scores indicate better functioning, while for symptom scales/items, higher scores indicate worse symptoms.

    Time frame: Up to 79 months

  23. Health Related Quality of Life (HRQoL) measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer Module (EORTC-QLQ-PAN-26)

    EORTC-QLQ-PAN26 is a 26-item questionnaire that evaluates pancreatic cancer-specific symptoms such as pain, dietary changes, jaundice, altered bowel habits, and emotional problems. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." For symptom scales/items, higher scores indicate worse symptoms.

    Time frame: Up to 79 months

  24. Health Related Quality of Life (HRQoL) measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L)

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome consisting of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale for health status. Each domain comprises 5 severity levels (no problems, slight problems, moderate problems, severe problems, extreme problems). The general visual analog scale records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples.

    Time frame: Up to 79 months

  25. Health Related Quality of Life (HRQoL) measured by the Patient Global Impression of Change (PGIC) scale

    The PGIC is a single-item questionnaire that asks participants to provide the overall self-assessment of change in their disease on a 7-point scale ranging from "very much worse" to "very much better" as compared to the participant starting the study treatment. Only PGIC questions assessing pain and overall status will be collected.

    Time frame: Up to 79 months

  26. Health Related Quality of Life (HRQoL) measured by the Patient Global Impression of Severity (PGIS) Scale

    The PGIS is a single-item questionnaire that asks participants to provide the overall self-assessment of their disease severity on a 4-point scale for the past week, with 1 as "None" and 4 as "Severe". Only PGIS questions assessing pain and overall status will be collected.

    Time frame: Up to 79 months

  27. Time to Improvement of pancreatic pain as measured by Quality-of-Life Questionnaire - Core Questionnaire (QLQ-C30)

    The QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." For functional scales, higher scores indicate better functioning, while for symptom scales/items, higher scores indicate worse symptoms.

    Time frame: Up to 79 months

  28. Time to worsening of global health status (GHS)/quality of life (QoL) as measured by QLQ-C30

    The QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." For functional scales, higher scores indicate better functioning, while for symptom scales/items, higher scores indicate worse symptoms.

    Time frame: Up to 79 months

  29. Time to Improvement of pancreatic pain as measured by Quality of Life Questionnaire - Pancreatic Cancer Module 26 (QLQ-PAN26)

    EORTC-QLQ-PAN26 is a 26-item questionnaire that evaluates pancreatic cancer-specific symptoms such as pain, dietary changes, jaundice, altered bowel habits, and emotional problems. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." For symptom scales/items, higher scores indicate worse symptoms.

    Time frame: Up to 79 months

  30. Time to worsening of GHS/QoL as measured by QLQ-PAN26

    EORTC-QLQ-PAN26 is a 26-item questionnaire that evaluates pancreatic cancer-specific symptoms such as pain, dietary changes, jaundice, altered bowel habits, and emotional problems. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." For symptom scales/items, higher scores indicate worse symptoms.

    Time frame: Up to 79 months

  31. Time to Improvement of pancreatic pain as measured by PGIS

    The PGIS is a single-item questionnaire that asks participants to provide the overall self-assessment of their disease severity on a 4-point scale for the past week, with 1 as "None" and 4 as "Severe". Only PGIS questions assessing pain and overall status will be collected.

    Time frame: Up to 79 months

  32. Time to worsening of GHS/QoL as measured by PGIS

    The PGIS is a single-item questionnaire that asks participants to provide the overall self-assessment of their disease severity on a 4-point scale for the past week, with 1 as "None" and 4 as "Severe". Only PGIS questions assessing pain and overall status will be collected.

    Time frame: Up to 79 months

07

Study locations

136 sites
  • St. Joseph Heritage Medical Group
    Fullerton, California 92835, United States
  • TOI Clinical research
    Whittier, California 90603, United States
  • Midstate Medical Center
    Meriden, Connecticut 06451, United States
  • Lynn Cancer Institute
    Boca Raton, Florida 33486, United States
  • Baptist Health
    Miami, Florida 33176, United States
  • Cancer Treatment Centers of Atlanta
    Newnan, Georgia 30265, United States
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
  • Norton Cancer Institute (NCI)
    Louisville, Kentucky 40202, United States
  • Ochsner Health System
    New Orleans, Louisiana 70121, United States
  • David C Pratt Cancer Center
    Creve Coeur, Missouri 63141, United States
  • Memorial Sloan Kettering Basking Ridge
    Basking Ridge, New Jersey 07920, United States
  • Memorial Sloan Kettering Bergen
    Montvale, New Jersey 07645, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14203, United States
  • Memorial Sloan Kettering Commack
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Westchester
    Harrison, New York 10604, United States
  • Northwell Health Cancer Institute
    Lake Success, New York 11042, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10022, United States
  • Memorial Sloan Kettering Nassau
    Uniondale, New York 11553, United States
  • Novant Health Presbyterian Medical Center
    Charlotte, North Carolina 28204, United States
  • Novant Health
    Winston-Salem, North Carolina 27103, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84106, United States
  • MultiCare Regional Cancer Center - Gig Harbor
    Gig Harbor, Washington 98335, United States
  • Vista Oncology
    Olympia, Washington 98502, United States
  • Virginia Mason
    Seattle, Washington 98101, United States
  • Site AU61008
    Gosford, New South Wales NSW 2250, Australia
  • Site AU61007
    Wollongong, New South Wales HVGM+3C, Australia
  • Site AU61005
    Fitzroy, Victoria 5XRF+WX, Australia
  • Site AU61006
    Warrnambool, Victoria VIC 3280, Australia
  • Site BR55012
    Porto Alegre, Rio Grande do Sul, Brazil
  • Site BR55009
    Centro Passo Fundo, Brazil
  • Site BR55008
    Rio Grande, Brazil
  • Site BR55004
    Santa Catarina, Brazil
  • Site BR55010
    São Paulo, Brazil
  • Site BR55011
    São Paulo, Brazil
  • Site CN86001
    Beijing, China
  • Site CN86008
    Beijing, China
  • Site CN86014
    Beijing, China
  • Site CN86026
    Changchun, China
  • Site CN86009
    Chongqing, China
  • Site CN86004
    Guangdong, China
  • Site CN86020
    Guangdong, China
  • Site CN86016
    Guangzhou, China
  • Site CN86012
    Harbin, China
  • Site CN86002
    Hubei, China
  • Site CN86005
    Jiangsu, China
  • Site CN86011
    Jiangsu, China
  • Site CN86025
    Jiangsu, China
  • Site CN86023
    Shandong, China
  • Site CN86006
    Shanghai, China
  • Site CN86013
    Shanghai, China
  • Site CN86019
    Shanghai, China
  • Site CN86024
    Shanxi, China
  • Site CN86007
    Tianjin, China
  • Site CN86022
    Xinjiang, China
  • Site CN86003
    Zhejiang, China
  • Site CN86018
    Zhejiang, China
  • Site CN86010
    Zhengzhou, China
  • Site FR33008
    Besançon, Besancon Cedex 6XG7+42, France
  • Site FR33010
    Brest, Brest Cedex 9GV7+4G, France
  • Site FR33015
    Caen, Cedex 5 14076, France
  • Site FR33006
    Chambray, Cedex 9 37170, France
  • Site FR33012
    Herblain, Herblain Cedex 44805, France
  • Site FR33016
    La Chaussée-Saint-Victor, Loir-et-Cher 41260, France
  • Site FR33009
    Nancy, Nancy Cedex 54000, France
  • Site FR33017
    Rouen, Normandy 76000, France
  • Site FR33003
    Aquitaine, Pessac 33604, France
  • Site FR33013
    Villejuif, Villejuif Cedex 94805, France
  • Site FR33001
    Bayonne, 64109, France
  • Site FR33018
    Bordeaux, France
  • Site FR33002
    Grenoble, France
  • Site FR33019
    La Roche-sur-Yon, France
  • Site FR33021
    Nice, France
  • Site FR33023
    Pierre-Bénite, France
  • Site FR33014
    Plérin, 22190, France
  • Site FR33005
    Pringy, 74374, France
  • Site FR33007
    Strasbourg, 67000, France
  • Site IR35301
    Elm Park, Dublin D04 T6F4, Ireland
  • Site IT39006
    Rozzano, Milan 20089, Italy
  • Site IT39004
    Candiolo, Torino 10060, Italy
  • Site IT39002
    Cremona, 26100, Italy
  • Site IT39010
    Lombardia, Italy
  • Site IT39003
    Milan, 20141, Italy
  • Site IT39014
    Toscana, Italy
  • Site IT39008
    Veneto, Italy
  • Site JP81007
    Nagoya, Aichi-ken, Japan
  • Site JP81001
    Kashiwa, Chiba, Japan
  • Site JP81005
    Sapporo, Hokkaido, Japan
  • Site JP81006
    Yokohama, Kanagawa, Japan
  • Site JP81003
    Kashihara, Nara, Japan
  • Site JP81011
    Bunkyo-ku, Tokyo, Japan
  • Site JP81012
    Chuo-ku, Tokyo, Japan
  • Site JP81014
    Koto-ku, Tokyo, Japan
  • Site JP81013
    Mitaka, Tokyo, Japan
  • Site JP81002
    Shinjuku-ku, Tokyo, Japan
  • Site JP81015
    Ube, Yamaguchi, Japan
  • Site JP81004
    Fukuoka, Japan
  • Site JP81010
    Osaka, Japan
  • Site JP81009
    Wakayama, Japan
  • Site MX52004
    Distrito Federal, Mexico

Showing the first 100 of 136 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for Oct 2026, 91 months after the start.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's planned 91 months is above that.

Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Aug 2026 → Oct 2026 and completion Aug 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2019
First posted
Jan 25, 2019
StartActual
Mar 15, 2019
Primary completionEst.
Oct 31, 2026was Aug 2026
CompletionEst.
Oct 31, 2026was Aug 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Oct 31, 2026
Oct 14, 2026
Study completion
Aug 31, 2026→Oct 31, 2026
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion Aug 31, 2026→Oct 31, 2026
    Study completion Aug 31, 2026→Oct 31, 2026
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03816163
Responsible party
Sponsor
First posted
Jan 25, 2019
Start date
Mar 15, 2019
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Oct 14, 2026

Study contacts

Medical Director
study director · Astellas Pharma Global Development

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zolbetuximab

Start the discussion